Clearmind Medicine announced that its independent DSMB unanimously approved moving CMND-100 into Parts B and C of the Phase I/II trial for alcohol use disorder, following Part A's favorable safety data. Part B tests 80 mg and 160 mg in AUD patients, while Part C evaluates a 160 mg daily dose in healthy participants, aiming to better characterize safety and early activity signals.
Clearmind Medicine Inc. announced that its CMND-100 drug candidate met primary safety endpoints in a Phase I/IIa trial for Alcohol Use Disorder. The positive results bolster confidence in advancing CMND-100 as a potential treatment, enhancing the company's position in the growing psychedelic therapeutics market.
